Please use this identifier to cite or link to this item: http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/8158
Title: NAD(P)H:Quinone Acceptor Oxidoreductase 1 (NQO1) Activatable Salicylamide H+/Cl− Transporters
Authors: ROY, NAVEEN J.
Save, Shreyada N.
SHARMA, VIRENDER KUMAR
ABRAHAM, BENCHAMIN
KUTTANAMKUZHI, ABHIJITH
Sharma, Shilpy
LAHIRI, MAYURIKA
TALUKDAR, PINAKI
Dept. of Biology
Dept. of Chemistry
Keywords: Antitumor agents
Apoptosis
Enzyme activation
ion transport
NQO1
2023-AUG-WEEK3
TOC-AUG-2023
2023
Issue Date: Sep-2023
Publisher: Wiley
Citation: Chemistry—A European Journal, 29(51).
Abstract: NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a detoxifying enzyme overexpressed in tumors, plays a key role in protecting cancer cells against oxidative stress and thus has been considered an attractive candidate for activating prodrug(s). Herein, we report the first use of NQO1 for the selective activation of ‘protransporter’ systems in cancer cells leading to the induction of apoptosis. Salicylamides, easily synthesizable small molecules, have been effectively used for efficient H+/Cl− symport across lipid membranes. The ion transport activity of salicylamides was efficiently abated by caging the OH group with NQO1 activatable quinones via either ether or ester linkage. The release of active transporters, following the reduction of quinone caged ‘protransporters’ by NQO1, was verified. Both the transporters and protransporters exhibited significant toxicity towards the MCF-7 breast cancer line, mediated via the induction of oxidative stress, mitochondrial membrane depolarization, and lysosomal deacidification. Induction of cell death via intrinsic apoptotic pathway was verified by monitoring PARP1 cleavage.
URI: https://doi.org/10.1002/chem.202301412
http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/8158
ISSN: 0947-6539
1521-3765
Appears in Collections:JOURNAL ARTICLES

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.